Limits...
Survival of patients treated with radiation therapy for anaplastic astrocytoma.

Barker CA, Chang M, Beal K, Chan TA - Radiol Oncol (2014)

Bottom Line: RTOG RPA class was associated with survival (p < 0.001), but use of temozolomide during or after RT was not (p > 0.05).In this retrospective study with inherent limitations, RTOG RPA classification was associated with survival.Further studies are necessary to confirm or refute this finding.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

ABSTRACT

Background: Anaplastic astrocytoma (AA) represents 7% of primary brain tumors in adults. Patient-, tumor-, and treatment-related factors are thought to be predictive of survival. We retrospectively assessed the association of patient-, tumor-, and treatment-related factors with survival in AA treated with radiotherapy (RT) at our institution.

Patients and methods: Medical records of patients with AA treated with RT between 1987 and 2007 were reviewed. Patient-, tumor-, and treatment-related variables were recorded and used to assign patients to a Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) classification. First use of chemotherapy was recorded. Log-rank tests and Cox regression models were used to assess for an association of patient-, tumor- and treatment-related factors with survival.

Results: One-hundred twenty-six patients were eligible for study. Median age, Karnofsky performance status, and duration of symptoms were 43 years, 90, and 8 weeks. Median radiation dose was 59.4 Gy; 61% of patients underwent tumor resection, and 17% and 41% of patients received temozolomide during and after RT. Median survival was 31 months, and 2-year survival was 58%. RTOG RPA class was associated with survival (p < 0.001), but use of temozolomide during or after RT was not (p > 0.05).

Conclusions: In this retrospective study with inherent limitations, RTOG RPA classification was associated with survival. Further studies are necessary to confirm or refute this finding.

No MeSH data available.


Related in: MedlinePlus

Survival of patients with anaplastic astrocytoma treated with radiation therapy, by concurrent use of temozolomide use during radiotherapy (n = 21) or no use of temozolomide during radiotherapy (n = 105). The log-rank test revealed no difference in survival by use or non-use of temozolomide during radiation therapy (RT; p = 0.28).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230558&req=5

f2-rado-48-04-381: Survival of patients with anaplastic astrocytoma treated with radiation therapy, by concurrent use of temozolomide use during radiotherapy (n = 21) or no use of temozolomide during radiotherapy (n = 105). The log-rank test revealed no difference in survival by use or non-use of temozolomide during radiation therapy (RT; p = 0.28).

Mentions: The log-rank test revealed no difference in survival between patients that were or were not taking TMZ during RT (p = 0.28), as displayed in Figure 2. Median survival of patients receiving TMZ during RT was 19 months, and median survival of patients not receiving TMZ during RT was 33 months; 2-year survival of patients receiving TMZ during was 46%, and 2-year survival of patients not receiving TMZ during RT was 60%.


Survival of patients treated with radiation therapy for anaplastic astrocytoma.

Barker CA, Chang M, Beal K, Chan TA - Radiol Oncol (2014)

Survival of patients with anaplastic astrocytoma treated with radiation therapy, by concurrent use of temozolomide use during radiotherapy (n = 21) or no use of temozolomide during radiotherapy (n = 105). The log-rank test revealed no difference in survival by use or non-use of temozolomide during radiation therapy (RT; p = 0.28).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230558&req=5

f2-rado-48-04-381: Survival of patients with anaplastic astrocytoma treated with radiation therapy, by concurrent use of temozolomide use during radiotherapy (n = 21) or no use of temozolomide during radiotherapy (n = 105). The log-rank test revealed no difference in survival by use or non-use of temozolomide during radiation therapy (RT; p = 0.28).
Mentions: The log-rank test revealed no difference in survival between patients that were or were not taking TMZ during RT (p = 0.28), as displayed in Figure 2. Median survival of patients receiving TMZ during RT was 19 months, and median survival of patients not receiving TMZ during RT was 33 months; 2-year survival of patients receiving TMZ during was 46%, and 2-year survival of patients not receiving TMZ during RT was 60%.

Bottom Line: RTOG RPA class was associated with survival (p < 0.001), but use of temozolomide during or after RT was not (p > 0.05).In this retrospective study with inherent limitations, RTOG RPA classification was associated with survival.Further studies are necessary to confirm or refute this finding.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

ABSTRACT

Background: Anaplastic astrocytoma (AA) represents 7% of primary brain tumors in adults. Patient-, tumor-, and treatment-related factors are thought to be predictive of survival. We retrospectively assessed the association of patient-, tumor-, and treatment-related factors with survival in AA treated with radiotherapy (RT) at our institution.

Patients and methods: Medical records of patients with AA treated with RT between 1987 and 2007 were reviewed. Patient-, tumor-, and treatment-related variables were recorded and used to assign patients to a Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) classification. First use of chemotherapy was recorded. Log-rank tests and Cox regression models were used to assess for an association of patient-, tumor- and treatment-related factors with survival.

Results: One-hundred twenty-six patients were eligible for study. Median age, Karnofsky performance status, and duration of symptoms were 43 years, 90, and 8 weeks. Median radiation dose was 59.4 Gy; 61% of patients underwent tumor resection, and 17% and 41% of patients received temozolomide during and after RT. Median survival was 31 months, and 2-year survival was 58%. RTOG RPA class was associated with survival (p < 0.001), but use of temozolomide during or after RT was not (p > 0.05).

Conclusions: In this retrospective study with inherent limitations, RTOG RPA classification was associated with survival. Further studies are necessary to confirm or refute this finding.

No MeSH data available.


Related in: MedlinePlus